title: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
abstract: OBJECTIVE
  To evaluate whether preoperative neoadjuvant chemotherapy in patients with primary operable breast cancer results in better overall survival (OS) and relapse-free survival rates and whether preoperative chemotherapy permits more breast-conserving surgery procedures than postoperative chemotherapy.
  
  
  METHODS
  Six hundred ninety-eight breast cancer patients (T1c, T2, T3, T4b, N0 to 1, and M0) were enrolled onto a randomized phase III trial that compared four cycles of fluorouracil, epirubicin, and cyclophosphamide administered preoperatively versus the same regimen administered postoperatively (the first cycle administered within 36 hours after surgery). Patients were followed up for OS, progression-free survival (PFS), and locoregional recurrence (LRR).
  
  
  RESULTS
  At a median follow-up of 56 months, there was no significant difference in terms of OS (hazards ratio, 1.16; P =.38), PFS (hazards ratio, 1.15; P =.27), and time to LRR (hazards ratio, 1.13; P =.61). Fifty-seven patients (23%) were downstaged by the preoperative chemotherapy, whereas 14 patients (18%) underwent mastectomy and not the planned breast-conserving therapy.
  
  
  CONCLUSIONS
  The use of preoperative chemotherapy yields similar results in terms of PFS, OS, and locoregional control compared with conventional postoperative chemotherapy. In addition, preoperative chemotherapy enables more patients to be treated with breast-conserving surgery. Because preoperative chemotherapy does not improve disease outcome compared with postoperative chemotherapy, future trials should involve quality-of-life studies to investigate whether patients will benefit from this treatment modality.
authors.affiliation: European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium. velde@lumc.nl
authors.forename: J A
authors.initials: JA
authors.lastname: van der Hage
authors.forename: C J
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: J P
authors.initials: JP
authors.lastname: Julien
authors.forename: M
authors.initials: M
authors.lastname: Tubiana-Hulin
authors.forename: C
authors.initials: C
authors.lastname: Vandervelden
authors.forename: L
authors.initials: L
authors.lastname: Duchateau
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015409:Mastectomy, Radical; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011300:Preoperative Care; D011788:Quality of Life; D011960:Receptors, Estrogen / Q000378:metabolism; D015996:Survival Rate
chemical_list: D011960:Receptors, Estrogen; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil